Led · Seed · Feb 2026

Entirety Biomedical is a Michigan-based medical device startup creating absorbable metal implants that offer titanium-like strength during healing and then safely resorb once bone union is achieved. Its patented Curasorb alloy underpins plate-and-screw and headless compression screw systems aimed initially at lower-extremity and maxillofacial procedures, allowing surgeons to avoid permanent hardware without changing existing surgical workflows or reimbursement models. The company completed its first preclinical study in 2024 and is running three additional preclinical studies, with early data showing strong osseointegration. These studies will guide a planned first-in-human clinical trial of its lower-extremity headless compression screw system. Entirety works closely with surgeons and strategic partners to identify unmet fixation needs and translate them into products that improve patient outcomes and reduce secondary removal surgeries. Founded by materials-science engineers Jake Edick and Carolyn Woldring, the team brings more than a decade of absorbable magnesium R&D experience and multiple related patents. The startup recently secured $1.2 million in seed funding to advance product development toward clinical trials.

Participated · Seed · Nov 2025

Founded in 2023, Big Rentals combines a national equipment rental marketplace with HQRent.com, its AI-driven operating software for small, independent rental companies. The platform automates scheduling, payments, and inventory, replacing paper and spreadsheets with modern digital workflows. By funneling new demand to local operators, Big Rentals increases fleet utilization and revenue opportunities across the United States. The company is headquartered in Los Angeles, CA and Nashville, TN, and it reports strong early traction in the construction and heavy-equipment segment through a nationwide partner network. Management plans to use its latest funding to accelerate expansion in that vertical and continue product development of its software suite. Big Rentals positions itself to capitalize on the $80+ billion U.S. equipment rental industry, which is growing alongside record manufacturing investment and infrastructure projects. Although specific revenue or user numbers were not disclosed, the company emphasizes unifying the fragmented long-tail of suppliers with a technology-first approach.

Participated · Series A · Dec 2024

TRIO Pharmaceuticals is a biotechnology company pioneering bispecific antibodies through its proprietary TRAILBody and TIE‑ADC platforms. Its dual‑action therapies aim to directly stop tumor growth while selectively reversing tumor immunosuppression without targeting existing immune checkpoints. TRIO is advancing programs against high‑mortality cancers including multiple myeloma, acute myeloid leukemia, ovarian, endometrial, and triple‑negative breast cancer. The company positions its therapies as potent, less toxic alternatives to conventional treatments and notes its team has developed first‑in‑class FDA‑approved drugs. TRIO will use proceeds to expand preclinical activities and advance its programs toward clinical development. The financing underscores a focus on accelerating development for cancers with high unmet need. TRIO Pharmaceuticals was founded by Purdue University biophysics and structural biology alumnus Shiva Bhowmik, who serves as founder and chief operating officer. The company develops antibody-based therapeutics intended to strengthen the body’s immune response by selectively eliminating immunosuppressive cells and directly targeting cancer cells. TRIO’s approach combines removal of immunosuppressive cells with direct anticancer activity to achieve stronger antitumor immunity. The recent financing is intended to enable TRIO to advance its technology and identify the best drug candidates for further development. Company leadership expects the milestone will open opportunities for collaborations with large pharmaceutical companies and the possibility of raising future funding rounds.

Participated · Seed · Feb 2024

ALT Sports Data offers a technology and services platform — described as a League Operating System — that bundles official data rights, integrity and compliance services, fan engagement and media tools, and commercial distribution across gaming and streaming. The platform is modular so leagues can adopt capabilities incrementally and scale into additional products over time. ASD works with more than 30 sports properties worldwide, including Formula 1, World Surf League, X Games, SuperMotocross World Championships, Bare Knuckle Fighting Championship, and Professional Bull Riders. The company has experienced significant growth over the past eighteen months and recently became Formula 1’s Official Betting Data Supplier. With the newly raised $5 million, ASD intends to invest further in product development, AI, league onboarding, integrity and compliance, sports betting and fan engagement offerings, and international expansion. The company continues to expand its global operator network and strategic services to create new commercial opportunities for leagues while maintaining control of audience and intellectual property.

Participated · Seed · Jan 2024

Vasa Therapeutics is a preclinical-stage biopharmaceutical company focused on therapies addressing the pathophysiology of cardiovascular aging. Its lead program, VS-041, is a personalized-medicine treatment for HFpEF that reduced cardiac fibrosis in a preclinical HFpEF model and inhibits release of collagen fragments such as PRO-C6; a Phase 1 clinical trial is planned for Q2 2024. Other programs include long-acting apelin peptide analogs intended for combination treatment with incretins in obesity patients at risk of muscle loss or cardiovascular disease, and potential monotherapy uses in muscle atrophy, heart failure, chronic kidney disease, and peripheral artery disease. The company is also developing a CamKIId inhibitor for heart failure and life-threatening arrhythmias. Vasa is led by CEO Artur Plonowski, MD, PhD, and is based in Encinitas, CA. It intends to use recently raised funds to advance these novel therapies toward clinical development.